Learn More

“For a patient with metastatic cancer, to think that there is a cancer treatment in development that could treat metastasis, and is potentially nontoxic… that’s life changing”

Josie Gardiner, Cancer Survivor
Learn More

“Having a therapy that can address established metastases would be an absolute game changer in the cancer field.”

Keith Flaherty, MD, Director of Clinical Research
Massachusetts General Hospital Cancer Center
Learn More

“9 out of 10 Cancer deaths are due to metastasis. We want to reverse that ratio and offer therapeutic options to patients that effectively treat their cancer.”

Anna Moore, PhD, TransCode Co-Founder
Professor of Radiology and Physiology, MSU
9 out of 10 deaths from cancer each year are due to metastasis

Our goal is to successfully treat metastatic disease by inactivating the survival mechanism of metastatic tumor cells. TransCode is developing a platform of targeted therapies with the goal of achieving lifelong regression of metastatic disease with no recurrence.

This year, more than 14 million people worldwide will learn they have cancer

and nearly 9 million people will lose their life to cancer. Cancer continues to be one of the leading causes of morbidity and mortality worldwide, but therapeutic innovation based on improved understanding of disease biology and translational research have considerably changed the treatment paradigm for many cancers.1 However, despite the many therapies and the billions of dollars spent each year, existing cancer treatments are only incrementally improving patient outcomes for late stage disease. It is now widely known that nine out of ten cancer deaths are due to metastasis and not the primary tumors from which they originate.

Learn More About the Problem

We have identified and are therapeutically targeting the biological mechanism responsible for metastasis

that we have termed “metastamiR dependence”. Our research shows that metastatic tumor cells cannot survive without the overexpression of a specific non-coding RNA molecule, microRNA-10b, which regulates the viability of metastatic tumor cells.

Learn More About the Solution

1. Global Oncology Trends 2017. IQVIA Report, May 31, 2017